Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.44 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183429 | 0.88 | SYK (0.52) | ABCG2ABCB1ABCC1LATS1LATS2 | |
| SCHEMBL16183433 | 0.87 | CYP1A2 (0.44) | ABCG2ABCB1LATS1LATS2SMN1; SMN2 | |
| SCHEMBL16183435 | 0.87 | SYK (0.46) | ABCG2ABCB1LATS1LATS2SMN1; SMN2 | |
| SCHEMBL16183432 | 0.87 | DHFR (0.48) | ABCG2ABCB1ABCC1LATS1LATS2 | |
| SCHEMBL16183427 | 0.86 | CYP1A2 (0.54) | ABCG2ABCB1LATS1LATS2SMN1; SMN2 | |
| SCHEMBL16183428 | 0.85 | CYP1A2 (0.52) | ABCG2ABCB1SMN1; SMN2MAPTTP53 | |
| SCHEMBL16183431 | 0.85 | SYK (0.44) | ABCG2ABCB1LATS1LATS2SMN1; SMN2 | |
| SCHEMBL16184164 | 0.84 | CYP1A2 (0.55) | LATS1LATS2SMN1; SMN2MAPTTP53 | |
| SCHEMBL16184179 | 0.84 | LATS1 (0.46) | LATS1LATS2SMN1; SMN2MAPTTP53 | |
| SCHEMBL16183728 | 0.84 | LATS1 (0.46) | LATS1LATS2SMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | ABCG2 1597/4885ABCB1 3803/4885ABCC1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.